Related articles

  • Randomized Controlled Trial

    Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

    Lancet. 2018 Dec 1; 392 (10162): 2367-2377.

  • Randomized Controlled Trial

    Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

    Lancet. 2018 Jun 23; 391 (10139): 2513-2524.

  • Randomized Controlled Trial

    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.

    Lancet. 2018 Oct 13; 392 (10155): 1330-1339.

    • Show more related articles...